The Munich-based medical technology company terraplasma medical GmbH – founded by terraplasma GmbH and Dynamify GmbH – has successfully completed its first financing round. Several private investors are jointly providing the company with a mid-seven-figure sum. The goal of this financing round is to enable the development and market approval of plasma care, a mobile, battery-operated medical device for the inpatient and outpatient treatment of chronic and acute wounds using cold plasma, which even kills fungi and multi-resistant bacteria.
Bacteria – especially multi-resistant germs – represent one of the biggest problems in poorly healing chronic and acute wounds. terraplasma medical's vision is to optimize the wound treatment process of medical professionals and to reduce patients' pain, thus improving their quality of life.
Mobile, battery-operated medical device for wound treatment
To achieve this vision, terraplasma medical A mobile, battery-operated medical device for the inpatient and outpatient treatment of chronic and acute wounds that uses cold plasma to kill even multi-resistant bacteria. Plasma is often referred to as the fourth state of matter (after solid, liquid, and gas) and describes a mixture of particles whose constituents are partially charged.
In a multi-center clinical study led by the Munich Schwabing Hospital and the Regensburg University Hospital in collaboration with Prof. Dr. Gregor Morfill and PD Dr. Julia Zimmermann, over 300 patients were treated with a stationary cold plasma device and the highly efficient bactericidal effect of cold plasmas in chronic and acute wounds on patients was proven.
“Extraordinarily well-connected group of investors”
The lead investors of the investor group, which is composed of industry-experienced investors, including those from the Business Angels Region Stuttgart (BARS) and the Munich area, are Gerd Reimann-Dubbers, Ali Alghanim, Rainer Baule and Fabian von Kuenheim.
“We are thrilled to have gained such an experienced and exceptionally well-connected group of investors to enable us to now implement our vision of an innovative wound treatment with cold plasma,”
is glad Jens Kirsch, Managing Director of terraplasma medical about the successful financing round.
As part of this financing round, a new advisory board was established, including Mr. Baule and Mr. von Kuenheim. The management is led by Dr. Julia Zimmermann and Mr. Jens Kirsch.
“We are very optimistic that, based on the management’s extensive experience and the clinical data already available, an innovative medical device for wound treatment can be approved within a reasonable period of time,”
justified Rainer Baule the investment.
